<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03163550</url>
  </required_header>
  <id_info>
    <org_study_id>ACHN-172-001</org_study_id>
    <nct_id>NCT03163550</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interaction Potential of ACHN-383 and ACHN-789</brief_title>
  <official_title>A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and the Drug-Drug Interaction Potential of Oral ACHN-383 and ACHN-789 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achaogen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Achaogen, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 clinical study is a double-blind, randomized, placebo-controlled, parallel group
      study to assess the safety, tolerability, pharmacokinetics (PK), food effect, and drug
      interaction potential of ACHN-383 and ACHN-789 co-administered orally as separate capsules in
      healthy subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 17, 2017</start_date>
  <completion_date type="Actual">October 15, 2017</completion_date>
  <primary_completion_date type="Actual">October 15, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in clinical laboratory values (CBC, serum chemistry, urine analysis, AST, ALT, ALP, serum bilirubin)</measure>
    <time_frame>26 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in vital signs (temperature, pulse, respiration, blood pressure)</measure>
    <time_frame>26 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>26 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in the QTcF interval</measure>
    <time_frame>19 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Maximum peak observed concentration (Cmax) after single-dose administration of ACHN-789</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Maximum peak observed concentration (Cmax) after single-dose administration of ACHN-383</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Time to maximum concentration (Tmax) after single-dose administration of ACHN-789</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Time to maximum concentration (Tmax) after single-dose administration of ACHN-383</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Area under the concentration-time curve (AUC) after single-dose administration of ACHN-789</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Area under the concentration-time curve (AUC) after single-dose administration of ACHN-383</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Half-life (t1/2) after single-dose administration of ACHN-789</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Half-life (t1/2) after single-dose administration of ACHN-383</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Apparent systemic clearance (CL/F) after single-dose administration of ACHN-789</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Apparent systemic clearance (CL/F) after single-dose administration of ACHN-383</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Apparent volume of distribution (Vz/F) after single-dose administration of ACHN-789</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Apparent volume of distribution (Vz/F) after single-dose administration of ACHN-383</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Amount excreted in urine (Ae) after single-dose administration of ACHN-789</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Amount excreted in urine (Ae) after single-dose administration of ACHN-383</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Renal clearance (CLr) after single-dose administration of ACHN-789</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Renal clearance (CLr) after single-dose administration of ACHN-383</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Cmax after single-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Cmax after single-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Tmax after single-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Tmax after single-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: AUC after single-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: AUC after single-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: t1/2 after single-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: t1/2 after single-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: CL/F after single-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: CL/F after single-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Vz/F after single-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Vz/F after single-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Ae after single-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Ae after single-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: CLr after single-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: CLr after single-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Cmax after single-dose administration of ACHN-383 and ACHN-789 given concurrently 30 minutes after a high-fat, high-calorie meal</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Tmax after single-dose administration of ACHN-383 and ACHN-789 given concurrently 30 minutes after a high-fat, high-calorie meal</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: AUC after single-dose administration of ACHN-383 and ACHN-789 given concurrently 30 minutes after a high-fat, high-calorie meal</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: t1/2 after single-dose administration of ACHN-383 and ACHN-789 given concurrently 30 minutes after a high-fat, high-calorie meal</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: CL/F after single-dose administration of ACHN-383 and ACHN-789 given concurrently 30 minutes after a high-fat, high-calorie meal</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Vz/F after single-dose administration of ACHN-383 and ACHN-789 given concurrently 30 minutes after a high-fat, high-calorie meal</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Ae after single-dose administration of ACHN-383 and ACHN-789 given concurrently 30 minutes after a high-fat, high-calorie meal</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: CLr after single-dose administration of ACHN-383 and ACHN-789 given concurrently 30 minutes after a high-fat, high-calorie meal</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Cmax after multiple-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Cmin after multiple-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Tmax after multiple-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: AUC after multiple-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: t1/2 after multiple-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: CL/F after multiple-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Vz/F after multiple-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Ae after multiple-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: CLr after multiple-dose administration of ACHN-383 and ACHN-789 given concurrently</measure>
    <time_frame>19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine concentrations of ACHN-789 after single dose administration</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine concentrations of ACHN-383 after single-dose administration</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine concentrations of ACHN-383 and ACHN-789 after single-dose administration given concurrently</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine concentrations of ACHN-383 and ACHN-789 after single-dose administration given concurrently</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine concentrations of ACHN-383 and ACHN-789 after multiple-dose administration given concurrently</measure>
    <time_frame>19 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACHN-383</intervention_name>
    <description>Oral dose</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACHN-789</intervention_name>
    <description>Oral dose</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral dose</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Females of child-bearing potential must not be breast feeding, must have a negative
             serum pregnancy test, and must use a highly effective method of contraception or be
             abstinent from sexual activity prior to the first dose of study, during the study and
             for a specified period following the last dose of study drug

          -  Males must be willing to use a condom for the duration of the study and for a
             specified period following the study, unless surgically sterile. In addition, their
             female partner must use a highly effective method of contraception, for the same
             period of time, unless surgically sterile

          -  Body mass index (BMI) of ≥19 kg/m^2 to ≤32 kg/m^2 and weight ≥50 kg to ≤125 kg

          -  Normal renal function as determined by creatinine clearance (CLcr) rate

        Key Exclusion Criteria:

          -  Pregnant women

          -  History of any hepatic or biliary disorder or disease

          -  Any condition that could possibly affect oral drug absorption

          -  Unstable cardiovascular disease

          -  Uncontrolled hypertension, asthma, diabetes, thyroid disease, or seizure disorder

          -  HIV positive

          -  Active malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel J Cloutier, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Achaogen, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2017</study_first_submitted>
  <study_first_submitted_qc>May 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2017</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

